InflaRx N.V. (NASDAQ: IFRX) announced the pricing of an underwritten offering of 75 million ordinary shares at $2.00 per share, raising $150 million in gross proceeds. The biopharmaceutical company expects the offering to close on May 7, 2026, subject to customary closing conditions.

The company plans to use net proceeds from the offering to advance its pipeline activities and for working capital and general corporate purposes, according to the press release statement.

The financing included participation from new and existing investors, including TCGX, Farallon Capital Management, Sirenia Capital Management LP, Columbia Threadneedle Investments, Great Point Partners LLC, ADAR1 Capital Management, Coastlands Capital, Squadron Capital Management and other mutual funds.

Guggenheim Securities is serving as lead bookrunner for the offering. Oppenheimer & Co. and LifeSci Capital are acting as bookrunners, while Raymond James and Needham & Company are co-lead managers. H.C. Wainwright & Co. and Lucid Capital Markets are serving as co-managers.

InflaRx develops anti-inflammatory therapeutics targeting the complement system. The company's lead program is izicopan, an oral small molecule inhibitor being developed for the treatment of AAV and additional renal diseases. The company also developed vilobelimab, an intravenous anti-C5a monoclonal antibody.

The offering is being conducted under a shelf registration statement that was declared effective by the Securities and Exchange Commission on July 11, 2023.